Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly nab-paclitaxel plus gemcitabine in elderly unresectable pancreatic cancer
jRCTs051190038Phase 2Completed
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC). Primary endpoint: Objective response rate. Started Aug 2019; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs051190038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190038.